Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00943527

Enrollment

110

Registered

2009-07-22

Start date

2008-01-31

Completion date

2012-01-31

Last updated

2012-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast, Menstrual Cycle, Breast Cancer, Hormone, MBI, Molecular Breast Imaging, Breast Imaging

Brief summary

This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

35 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

Arm 1 Inclusion Criteria: * age 35-45 * have regular menstrual cycles as defined by having menstrual cycle length of 25-31 days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding. * have had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.

Exclusion criteria

* currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors * have a personal history of any cancer, except non-melanomatous skin cancer * unable to understand and sign the consent form * pregnant or lactating * physically unable to sit upright and still for 30 minutes Arm 2 Inclusion Criteria: * scheduled to begin one of the following regimens of HT: * Any dosage of any formulation of systemic estrogen therapy in the setting of a prior hysterectomy * Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the progesterone therapy is the oral, micronized formulation * had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.

Countries

United States

Outcome results